Member
2 Awards

Prytime Medical Devices, Inc.


Prytime Medical Devices, Inc. is an innovative medical device company that designs, develops, and commercializes minimally invasive solutions for hemorrhage control, particularly through the use of the Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) technique. The company aims to improve survival rates in trauma situations where hemorrhage is the leading cause of potentially survivable death. Prytime is committed to revolutionizing the care of severely injured patients by enabling trauma teams to gain control of life-threatening bleeding as a bridge to definitive repair.

Industries

N/A

Nr. of Employees

small (1-50)

Prytime Medical Devices, Inc.

12 Upper Balcones Rd, Suite 300, Boerne, TX 78006

Awards

Fiscal Year 2024 Military Prototype Advancement Initiative (MPAI)

A Study of Partial REBOA Use on the Battlefield: Enabling Transport of Combat Casualties with NCTH

Funding (ceiling)

$1,393,019.31

Award Year

2024

Military Prototype Advancement Initiative (MPAI)

Real-World Observational Study of pREBOA-PRO Use and Partial REBOA in Hemorrhaging Patients

Funding (ceiling)

$6,216,488.29

Award Year

2022


Patents

Vascular occlusion catheter for partial occlusion or full occlusion

2024-10-01 • US-12102330-B2

View Details

Occlusion catheter system for full or partial occlusion

2024-06-18 • US-12011172-B2

View Details

System and method for low-profile occlusion balloon catheter

2024-01-02 • US-11857737-B2

View Details

System and method for low-profile occlusion balloon catheter

2023-06-13 • US-11672951-B2

View Details

System and method for low profile occlusion balloon catheter

2022-02-22 • US-11253264-B2

View Details

Handheld multi-needle vascular access device

2020-10-20 • US-10806903-B2

View Details
View All Patents

Products

Endovascular balloon occlusion catheter (7 Fr-compatible)

Sterile endovascular balloon occlusion catheter designed for rapid aortic occlusion with features for integrated pressure monitoring, atraumatic tip geometry, radiopaque markers and rapid-insertion aids.

Partial aortic-occlusion catheter

Balloon catheter product designed to enable controlled partial aortic occlusion to support titrated hemorrhage control strategies and mitigate ischemic and reperfusion injury.

Femoral access and procedure convenience kit

Pre-assembled kit containing components required for femoral arterial access, catheter placement and external fixation; regional kit contents may vary.

High-fidelity arterial access and REBOA simulator

A simulation trainer combining a physical arterial access model with electronic hemodynamic simulation (pressure transducers, tablet control, pump and replaceable artery tubes) and ultrasound-compatible access patches for hands-on training.

Expertise Areas

  • Endovascular hemorrhage control
  • Catheter design and development for emergent vascular occlusion
  • Partial aortic occlusion techniques and device-based titration
  • Simulation-based procedural training and curriculum support
  • Show More (6)

Key Technologies

  • Resuscitative endovascular balloon occlusion (REBOA) techniques
  • Partial aortic occlusion (titrated/partial occlusion) methods
  • Integrated real-time central aortic pressure monitoring in catheters
  • Guidewire-free catheter insertion using flexible hypotube (nitinol) constructions
  • Show More (6)

Key People

President & Chief Executive Officer

Senior Vice President, Research and Product Development

Chief Financial Officer

Senior Vice President, Quality & Regulatory

Chief Commercialization Officer


News & Updates

Prytime Medical has announced a significant donation to support medical aid and training in Ukraine.

Prytime Medical has appointed Dr. M. Chance Spalding as the new Chief Medical Officer.

Prytime Medical's products may be covered by various patents in the U.S. and internationally, including patents for REBOA catheters and simulators.


Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.